Most Popular Peptides in 2026: What 2,209 Patients Ordered
Tirzepatide is the most ordered product at Rx Peps Direct: 27% of our 2,209 patients have ordered it. KLOW comes second at 20%, then NAD+ at 16% and the Wolverine stack at 15%. Half of all orders combine two or more products, and the single most common pair is KLOW with tirzepatide. Men and women order very differently: 38% of women have ordered tirzepatide against 19% of men, and 20% of men have ordered the Wolverine stack against 7% of women.
7 min read · Updated November 7, 2026
By Marcus HansenFounder & CEO, Rx Peps DirectWhere does this data come from?
It comes from every paid order placed through Rx Peps Direct between May 13 and November 6, 2026: 4,099 orders from 2,209 patients. Every order went through a $39 medical review by a licensed provider before anything went to the pharmacy.
| Counted | Every paid order, whether the provider approved it, was still reviewing it, or did not approve it. Refills count as new orders. |
| Removed | Test accounts and checkouts that were never paid. |
| Patients | Matched by email address. A person who used two email addresses counts twice. |
| Men and women | The biological sex the patient entered at intake: 1,278 men and 930 women. |
| Products | Grouped across dose and form. Tirzepatide/B12, tirzepatide microdose and tirzepatide with B6 and glycine all count as tirzepatide. NAD+ injection and nasal spray count as NAD+. High-dose versions count with their base product. |
| Cart contents | What the patient checked out with. A few items a provider later declined are still counted. |
These numbers describe Rx Peps Direct patients. They are not a national estimate of peptide use.
Which peptides do patients order most?
Tirzepatide, by a wide margin. These are the ten products the most patients have ordered at least once.
| Product | Patients | Share of patients |
|---|---|---|
| Tirzepatide | 587 | 26.6% |
| KLOW (BPC-157, TB-500, KPV and GHK-Cu) | 439 | 19.9% |
| NAD+ | 350 | 15.8% |
| Wolverine stack (BPC-157 and TB-500) | 321 | 14.5% |
| CJC-1295/Ipamorelin | 297 | 13.4% |
| BPC-157 | 257 | 11.6% |
| MOTS-C | 251 | 11.4% |
| GHK-Cu (injectable) | 242 | 11.0% |
| Semax/Selank | 181 | 8.2% |
| Tesamorelin | 173 | 7.8% |
Three of the top six contain BPC-157: KLOW, the Wolverine stack and BPC-157 on its own. Tirzepatide is also the most common first order: 468 patients started with it.
Which peptides are ordered together most often?
KLOW with tirzepatide (97 orders) and KLOW with NAD+ (96 orders). KLOW appears in four of the five most common pairs.
| Pair | Orders with both |
|---|---|
| KLOW + tirzepatide | 97 |
| KLOW + NAD+ | 96 |
| KLOW + CJC-1295/Ipamorelin | 87 |
| NAD+ + tirzepatide | 72 |
| KLOW + MOTS-C | 58 |
| Wolverine stack + CJC-1295/Ipamorelin | 57 |
| MOTS-C + NAD+ | 54 |
| CJC-1295/Ipamorelin + MOTS-C | 45 |
| KLOW + Lean Stack | 45 |
| MOTS-C + SS-31 | 45 |
Stacking is normal here. 49% of orders hold two or more products, and 26% hold three or more. One $39 medical review covers up to three products, and more orders use all three (1,082) than stop at two (935). Our guide to how many peptides you can stack covers how providers think about combinations.
The most common three-product orders are CJC-1295/Ipamorelin + KLOW + tirzepatide (13 orders), KLOW + NAD+ + tirzepatide (13), CJC-1295/Ipamorelin + KLOW + MOTS-C (11) and MOTS-C + NAD+ + SS-31 (11).
What do people order with tirzepatide?
Usually nothing. 56% of the 991 orders that included tirzepatide had no other product in them. When patients do add something, KLOW and NAD+ lead.
| Added in the same order | Orders | Share of tirzepatide orders |
|---|---|---|
| KLOW | 97 | 9.8% |
| NAD+ | 72 | 7.3% |
| CJC-1295/Ipamorelin | 42 | 4.2% |
| Lean Stack | 33 | 3.3% |
| GHK-Cu (injectable) | 29 | 2.9% |
| Lipo-C | 29 | 2.9% |
| MOTS-C | 28 | 2.8% |
| Tesamorelin/Ipamorelin | 28 | 2.8% |
| Wolverine stack | 28 | 2.8% |
| BPC-157/TB-500/KPV | 26 | 2.6% |
Across all their orders, 20% of tirzepatide patients have also ordered KLOW and 15% have ordered NAD+. Glutathione is the one product tirzepatide patients order noticeably more often than everyone else: 7.2% of them, against 4.9% of other patients.
Tirzepatide patients are 59% women, so compare this table with the men and women split below before reading too much into any one line. For the medication itself, see compounded tirzepatide vs Mounjaro vs Zepbound.
Do men and women order different peptides?
Yes. Women's orders center on tirzepatide, NAD+ and GHK-Cu. Men's orders center on BPC-157, TB-500 and the growth-hormone-releasing peptides.
The biggest gaps:
- Women order semaglutide at 3.1 times the men's rate, injectable GHK-Cu at 2.6 times and tirzepatide at 2.0 times.
- Men order tesamorelin at 3.4 times the women's rate, the Wolverine stack at 3.0 times and CJC-1295/Ipamorelin at 2.4 times.
- KLOW is the one top product ordered at almost the same rate by both (19% of men, 21% of women).
Men spend a little more per order: an average of $175 in pharmacy pricing against $154 for women. Men and women place about the same number of orders each: 1.88 per man and 1.82 per woman. More on each group in peptides for women and peptides for men.
How old are peptide patients?
The median patient is 45. The youngest is 18 and the oldest is 88.
| Age | Patients | Most ordered product | Share of that age group |
|---|---|---|---|
| 20s | 152 | Tirzepatide | 28% |
| 30s | 505 | Tirzepatide | 31% |
| 40s | 740 | Tirzepatide | 26% |
| 50s | 547 | Tirzepatide | 24% |
| 60s | 194 | Tirzepatide | 22% |
| 70s | 50 | Tirzepatide | 24% |
People in their 40s are the largest group, and tirzepatide is the most ordered product in every decade from the 20s to the 70s. KLOW is second, or tied for second, in every decade except the 60s, where the Wolverine stack is second at 19%.
Which peptides do patients reorder most?
Tesamorelin/Ipamorelin and CJC-1295/Ipamorelin. Of patients whose first order included one of them, 80% and 74% have ordered again. This counts only patients whose first order is at least 45 days old.
| First order included | Patients | Reordered | Reorder rate |
|---|---|---|---|
| Tesamorelin/Ipamorelin | 64 | 51 | 80% |
| CJC-1295/Ipamorelin | 152 | 112 | 74% |
| MOTS-C | 79 | 56 | 71% |
| Tirzepatide | 249 | 176 | 71% |
| Wolverine stack | 120 | 84 | 70% |
| KLOW | 194 | 125 | 64% |
| GHK-Cu (injectable) | 110 | 68 | 62% |
| NAD+ | 143 | 85 | 59% |
| BPC-157 | 98 | 50 | 51% |
| Semax/Selank | 60 | 27 | 45% |
| PT-141 | 44 | 17 | 39% |
Overall, 44% of patients (968) have placed more than one order. One patient has placed 19.
What do returning patients add on later orders?
MOTS-C and tirzepatide, each added by 119 returning patients who had not ordered them the first time. NAD+ is next (100), then KLOW (94), skin and hair topicals, mostly GHK-Cu (71), Semax/Selank (60), glutathione (58) and SS-31 (57).
Where do peptide patients live?
Texas, by a wide margin: 622 patients, or 28% of the total. Florida is second with 386 (17%).
| State | Patients | Share |
|---|---|---|
| Texas | 622 | 28.2% |
| Florida | 386 | 17.5% |
| New York | 159 | 7.2% |
| New Jersey | 110 | 5.0% |
| Washington | 107 | 4.8% |
| Colorado | 105 | 4.8% |
| Arizona | 90 | 4.1% |
| Pennsylvania | 77 | 3.5% |
How fast are orders growing?
Monthly orders went from 33 in May 2026 to 1,522 in October 2026.
| Month (2026) | Paid orders |
|---|---|
| May (from May 13) | 33 |
| June | 64 |
| July | 298 |
| August | 639 |
| September | 1,176 |
| October | 1,522 |
Can I use this data?
Yes. Quote or chart any number on this page with a link to this page as the source. For the full tables or a cut we have not shown here, email support@rxpepsdirect.com with "Data request" in the subject line.
How does Rx Peps Direct work?
Rx Peps Direct is an online peptide clinic. You pick up to three products, a licensed provider reviews your intake for a $39 medical review, and approved orders go to a licensed pharmacy that ships to you. There is no subscription.
Start a $39 medical review or read whether Rx Peps Direct is legit.
Continue reading